Critical Outcome Advances To Fourth Cohort In Phase 1 Study of COTI-2 In Gynecologic Cancers
Critical Outcome Technologies Inc. (“COTI” or the “Company”) (TSX Venture: COT; OTCQB: COTQF), a clinical stage biotechnology company advancing a pipeline of targeted therapies for the treatment of cancer, announced today that the Company has commenced dosing women in the fourth cohort of its ongoing Phase 1 clinical trial of COTI-2 intended for the treatment…